drugset
Drugs / H5 VLP vaccine
last change Nov 2014 re-read 2 minutes ago

H5 VLP vaccine

also known as H5 VLP pandemic influenza vaccine · plant-made H5 VLP vaccine

Vaccine

Developed for
respiratory tract infectious disorder · viral infectious disease
Investigated by
McGill University Health Centre/Research Institute of the McGill University Health Centre · Medicago · Syneos Health

Trials 1 · a red edge is where a trial was stopped

today NCT01991561 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01991561 Jun 2013 → Jul 2014 respiratory tract infectious disorder, viral infectious disease Medicago Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00984945 Comparator Sep → Dec 2009 respiratory tract infectious disorder, viral infectious disease Medicago Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as H5 VLP vaccine “We further report on safety and immunogenicity from a Phase I clinical study of the plant-made H5 VLP vaccine in healthy adults 18-60 years of age who received 2 doses 21 days...” PMID 21203523 ↗ Dec 2010
1

NCT01991561 ↗
Known as H5 VLP pandemic influenza vaccine “H5 VLP pandemic influenza vaccine 5 µg” NCT00984945 ↗
Known as plant-made H5 VLP vaccine “We further report on safety and immunogenicity from a Phase I clinical study of the plant-made H5 VLP vaccine in healthy adults 18-60 years of age who received 2 doses 21 days...” PMID 21203523 ↗ Dec 2010
Modality Vaccine “candidate Virus-Like Particle (VLP) vaccine” PMID 21203523 ↗ Dec 2010
Route Intramuscular “0.5 mL, IM, 2 injections 21 days apart” NCT00984945 ↗